The importance of ether-phospholipids: A view from the perspective of mouse models

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 9, 2012, Pages 1501-1508

  Da Silva, Tiago Ferreira ^a,b   Sousa, Vera F ^a,b   Malheiro, Ana R ^a   Brites, Pedro ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Disease mechanism; Knockout; Nervous tissue; Oxidative stress; Peroxisome; Plasmalogen

Indexed keywords

ETHER PHOSPHOLIPID; PLASMALOGEN;

CELL DIFFERENTIATION; CELL VACUOLE; CHONDRODYSPLASIA PUNCTATA; EYE DISEASE; GENE MUTATION; HISTOPATHOLOGY; LENS FIBER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE HYPOPLASIA; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SEMINIFEROUS TUBULE;

ANIMALS; CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC; DISEASE MODELS, ANIMAL; GLUCOSAMINE 6-PHOSPHATE N-ACETYLTRANSFERASE; HUMANS; MICE; MICE, KNOCKOUT; PLASMALOGENS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84864039497     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.05.014     Document Type: Review

References (114)

1. Goldfischer S., Johnson A.B., Essner E., Moore C., Ritch R.H. Peroxisomal abnormalities in metabolic diseases. J. Histochem. Cytochem. 1973, 21:972-977.
2. Goldfischer S., Moore C.L., Johnson A.B., Spiro A.J., Valsamis M.P., Wisniewski H.K., Ritch R.H., Norton W.T., Rapin I., Gartner L.M. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 1973, 182:62-64.
3. Steinberg S.J., Dodt G., Raymond G.V., Braverman N.E., Moser A.B., Moser H.W. Peroxisome biogenesis disorders. Biochim. Biophys. Acta 2006, 1763:1733-1748.
4. Tabak H.F., Murk J.L., Braakman I., Geuze H.J. Peroxisomes start their life in the endoplasmic reticulum. Traffic 2003, 4:512-518.
5. Wanders R.J., Waterham H.R. Biochemistry of mammalian peroxisomes revisited. Annu. Rev. Biochem. 2006, 75:295-332.
6. Faust P.L., Banka D., Siriratsivawong R., Ng V.G., Wikander T.M. Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain. J. Inherit. Metab. Dis. 2005, 28:369-383.
7. Wanders R.J., Ferdinandusse S., Brites P., Kemp S. Peroxisomes, lipid metabolism and lipotoxicity. Biochim. Biophys. Acta 2010, 1801:272-280.
8. Wiese S., Gronemeyer T., Ofman R., Kunze M., Grou C.P., Almeida J.A., Eisenacher M., Stephan C., Hayen H., Schollenberger L., Korosec T., Waterham H.R., Schliebs W., Erdmann R., Berger J., Meyer H.E., Just W., Azevedo J.E., Wanders R.J., Warscheid B. Proteomic characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling. Mol. Cell. Proteomics 2007, 6:2045-2057.
9. Baes M., Gressens P., Baumgart E., Carmeliet P., Casteels M., Fransen M., Evrard P., Fahimi D., Declercq P.E., Collen D., Van Veldhoven P.P., Mannaerts G.P. A mouse model for Zellweger syndrome. Nat. Genet. 1997, 17:49-57.
10. Baes M. Mouse models for peroxisome biogenesis disorders. Cell Biochem. Biophys. Spring 2000, 32:229-237.
11. Maxwell M., Bjorkman J., Nguyen T., Sharp P., Finnie J., Paterson C., Tonks I., Paton B.C., Kay G.F., Crane D.I. Pex13 inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype. Mol. Cell. Biol. 2003, 23:5947-5957.
12. Li X., Baumgart E., Morrell J.C., Jimenez-Sanchez G., Valle D., Gould S.J. PEX11 beta deficiency is lethal and impairs neuronal migration but does not abrogate peroxisome function. Mol. Cell. Biol. 2002, 22:4358-4365.
13. Faust P.L., Su H.M., Moser A., Moser H.W. The peroxisome deficient PEX2 Zellweger mouse: pathologic and biochemical correlates of lipid dysfunction. J. Mol. Neurosci. 2001, 16:289-297.
14. Heinzer A.K., McGuinness M.C., Lu J.F., Stine O.C., Wei H., Van der Vlies M., Dong G.X., Powers J., Watkins P.A., Smith K.D. Mouse models and genetic modifiers in X-linked adrenoleukodystrophy. Adv. Exp. Med. Biol. 2003, 544:75-93.
15. Kobayashi T., Shinnoh N., Kondo A., Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem. Biophys. Res. Commun. 1997, 232:631-636.
16. Lu J.F., Lawler A.M., Watkins P.A., Powers J.M., Moser A.B., Moser H.W., Smith K.D. A mouse model for X-linked adrenoleukodystrophy. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9366-9371.
17. Pujol A., Hindelang C., Callizot N., Bartsch U., Schachner M., Mandel J.L. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet. 2002, 11:499-505.
18. Ferdinandusse S., Zomer A.W., Komen J.C., van den Brink C.E., Thanos M., Hamers F.P., Wanders R.J., Van Der Saag P.T., Poll-The B.T., Brites P. Ataxia with loss of Purkinje cells in a mouse model for Refsum disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17712-17717.
19. Baes M., Huyghe S., Carmeliet P., Declercq P.E., Collen D., Mannaerts G.P., Van Veldhoven P.P. Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J. Biol. Chem. 2000, 275:16329-16336.
20. Baes M., Gressens P., Huyghe S., De N.K., Qi C., Jia Y., Mannaerts G.P., Evrard P., Van V.P., Declercq P.E., Reddy J.K. The neuronal migration defect in mice with Zellweger syndrome (Pex5 knockout) is not caused by the inactivity of peroxisomal beta-oxidation. J. Neuropathol. Exp. Neurol. 2002, 61:368-374.
21. Baes M., Van Veldhoven P.P. Mouse models for peroxisome biogenesis defects and β-oxidation enzyme deficiencies. Biochim. Biophys. Acta 2012, 1822:1489-1500.
22. Paltauf F. Ether lipids in biomembranes. Chem. Phys. Lipids 1994, 74:101-139.
23. Paltauf F., Hermetter A. Properties of ether lipids in biological-membranes. FASEB J. 1988, 2:A1740.
24. Le B.K., Samuelsson J., Brohult J., Berg A., Palmblad J. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine-a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism. Biochem. Pharmacol. 1995, 49:1577-1582.
25. Brites P., Waterham H.R., Wanders R.J. Functions and biosynthesis of plasmalogens in health and disease. Biochim. Biophys. Acta 2004, 1636:219-231.
26. Lessig J., Fuchs B. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr. Med. Chem. 2009, 16:2021-2041.
27. Wallner S., Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids 2011, 164:573-589.
28. Gilbert E.F., Opitz J.M., Spranger J.W., Langer L.O., Wolfson J.J., Viseskul C. Chondrodysplasia punctata-rhizomelic form. Pathologic and radiologic studies of three infants. Eur. J. Pediatr. 1976, 123:89-109.
29. Wardinsky T.D., Pagon R.A., Powell B.R., McGillivray B., Stephan M., Zonana J., Moser A. Rhizomelic chondrodysplasia punctata and survival beyond one year: a review of the literature and five case reports. Clin. Genet. 1990, 38:84-93.
30. White A.L., Modaff P., Holland-Morris F., Pauli R.M. Natural history of rhizomelic chondrodysplasia punctata. Am. J. Med. Genet. A 2003, 118A:332-342.
31. Poulos A., Sheffield L., Sharp P., Sherwood G., Johnson D., Beckman K., Fellenberg A.J., Wraith J.E., Chow C.W., Usher S. Rhizomelic chondrodysplasia punctata: clinical, pathologic, and biochemical findings in two patients. J. Pediatr. 1988, 113:685-690.
32. Wells T.R., Landing B.H., Bostwick F.H. Studies of vertebral coronal cleft in rhizomelic chondrodysplasia punctata. Pediatr. Pathol. 1992, 12:593-600.
33. Bams-Mengerink A.M., Majoie C.B., Duran M., Wanders R.J., Van Hove J., Scheurer C.D., Barth P.G., Poll-The BT MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 2006, 66:798-803.
34. Lenti C., Paganoni P., Sangermani R. Rhizomelic chondrodysplasia punctata: 16-year follow-up of a child from birth. Ital. J. Neurol. Sci. 1991, 12:469-473.
35. Goh S. Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata. Pediatr. Neurol. 2007, 37:382-384.
36. Alkan A., Kutlu R., Yakinci C., Sigirci A., Aslan M., Sarac K. Delayed myelination in a rhizomelic chondrodysplasia punctata case: MR spectroscopy findings. Magn. Reson. Imaging 2003, 21:77-80.
37. Sztriha L., Al-Gazali L.I., Wanders R.J., Ofman R., Nork M., Lestringant G.G. Abnormal myelin formation in rhizomelic chondrodysplasia punctata type 2 (DHAPAT-deficiency). Dev. Med. Child Neurol. 2000, 42:492-495.
38. Braverman N., Chen L., Lin P., Obie C., Steel G., Douglas P., Chakraborty P.K., Clarke J.T., Boneh A., Moser A., Moser H., Valle D. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum. Mutat. 2002, 20:284-297.
39. Motley A.M., Brites P., Gerez L., Hogenhout E., Haasjes J., Benne R., Tabak H.F., Wanders R.J., Waterham H.R. Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am. J. Hum. Genet. 2002, 70:612-624.
40. Purdue P.E., Skoneczny M., Yang X., Zhang J.W., Lazarow P.B. Rhizomelic chondrodysplasia punctata, a peroxisomal biogenesis disorder caused by defects in Pex7p, a peroxisomal protein import receptor: a minireview. Neurochem. Res. 1999, 24:581-586.
41. Lazarow P.B. The import receptor Pex7p and the PTS2 targeting sequence. Biochim. Biophys. Acta 2006, 1763:1599-1604.
42. Ofman R., Hettema E.H., Hogenhout E.M., Caruso U., Muijsers A.O., Wanders R.J. Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum. Mol. Genet. 1998, 7:847-853.
43. Biermann J., Gootjes J., Humbel B.M., Dansen T.B., Wanders R.J., van den Bosch H. Immunological analyses of alkyl-dihydroxyacetone-phosphate synthase in human peroxisomal disorders. Eur. J. Cell Biol. 1999, 78:339-348.
44. de Vet E.C., Ijlst L., Oostheim W., Wanders R.J., van den Bosch H. Alkyl-dihydroxyacetonephosphate synthase. Fate in peroxisome biogenesis disorders and identification of the point mutation underlying a single enzyme deficiency. J. Biol. Chem. 1998, 273:10296-10301.
45. de Vet E.C., van den Bosch H. Alkyl-dihydroxyacetonephosphate synthase. Cell Biochem. Biophys. Spring 2000, 32:117-121.
46. Powers J.M., Moser H.W. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol. 1998, 8:101-120.
47. Powers J.M., Kenjarski T.P., Moser A.B., Moser H.W. Cerebellar atrophy in chronic rhizomelic chondrodysplasia punctata: a potential role for phytanic acid and calcium in the death of its Purkinje cells. Acta Neuropathol. 1999, 98:129-134.
48. Van den Brink D.M., Brites P., Haasjes J., Wierzbicki A.S., Mitchell J., Lambert-Hamill M., de B.J., Jansen G.A., Waterham H.R., Wanders R.J. Identification of PEX7 as the second gene involved in Refsum disease. Am. J. Hum. Genet. 2003, 72:471-477.
49. Elias E.R., Mobassaleh M., Hajra A.K., Moser A.B. Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetonephosphate acyltransferase (DHAP-AT) deficiency. Am. J. Med. Genet. 1998, 80:223-226.
50. Motley A.M., Tabak H.F., Smeitink J.A., Poll-The B.T., Barth P.G., Wanders R.J. Non-rhizomelic and rhizomelic chondrodysplasia punctata within a single complementation group. Biochim. Biophys. Acta 1996, 1315:153-158.
51. Datta N.S., Wilson G.N., Hajra A.K. Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome. A new category of metabolic disease involving the absence of peroxisomes. N. Engl. J. Med. 1984, 311:1080-1083.
52. Schutgens R.B., Wanders R.J., Nijenhuis A., van den Hoek C.M., Heymans H.S., Schrakamp G., Bleeker-Wagemakers E.M., Delleman J.W., Schram A.W., Tager J.M. Genetic diseases caused by peroxisomal dysfunction. New findings in clinical and biochemical studies. Enzyme 1987, 38:161-176.
53. Gootjes J., Mooijer P.A., Dekker C., Barth P.G., Poll-The B.T., Waterham H.R., Wanders R.J. Biochemical markers predicting survival in peroxisome biogenesis disorders. Neurology 2002, 59:1746-1749.
54. Wilson G.N., Holmes R.G., Custer J., Lipkowitz J.L., Stover J., Datta N., Hajra A. Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am. J. Med. Genet. 1986, 24:69-82.
55. Powers J.M. Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders. J. Mol. Neurosci. 2001, 16:285-287.
56. Weller S., Rosewich H., Gartner J. Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients. J. Inherit. Metab. Dis. 2008.
57. Nakai A., Shigematsu Y., Nishida K., Kikawa Y., Konishi Y. MRI findings of Zellweger syndrome. Pediatr. Neurol. 1995, 13:346-348.
58. Lindhard A., Graem N., Skovby F., Jeppesen D. Postmortem findings and prenatal diagnosis of Zellweger syndrome. Case report. APMIS 1993, 101:226-228.
59. Khan M., Singh J., Singh I. Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J. Neurochem. 2008, 106:1766-1779.
60. Saitoh M., Yamashita S., Shimozawa N., Mizuguchi M., Iwamori M. Changes in the amounts of myelin lipids and molecular species of plasmalogen PE in the brain of an autopsy case with D-bifunctional protein deficiency. Neurosci. Lett. 2008, 442:4-9.
61. Aubourg P., Dubois-Dalcq M. X-linked adrenoleukodystrophy enigma: how does the ALD peroxisomal transporter mutation affect CNS glia?. Glia 2000, 29:186-190.
62. Powers J.M. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin. Neuropathol. 1985, 4:181-199.
63. Aubourg P., Adamsbaum C., Lavallard-Rousseau M.C., Lemaitre A., Boureau F., Mayer M., Kalifa G. Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy. Neurology 1992, 42:85-91.
64. Johnson A.B., Schaumburg H.H., Powers J.M. Histochemical characteristics of the striated inclusions of adrenoleukodystrophy. J. Histochem. Cytochem. 1976, 24:725-730.
65. Berger J., Gartner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim. Biophys. Acta 2006, 1763:1721-1732.
66. Igarashi M., Schaumburg H.H., Powers J., Kishmoto Y., Kolodny E., Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem. 1976, 26:851-860.
67. Johnson A.B., Schaumburg H.H., Powers J.M. Histochemical characteristics of the striated inclusions of adrenoleukodystrophy. J. Histochem. Cytochem. 1976, 24:725-730.
68. Schaumburg H.H., Powers J.M., Raine C.S., Johnson A.B., Kolodny E.H., Kishimoto Y., Igarashi M., Suzuki K. Adrenoleukodystrophy: a clinical, pathological and biochemical study. Adv. Exp. Med. Biol. 1976, 68:379-387.
69. Kemp S., Theodoulou F.L., Wanders R.J. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br. J. Pharmacol. 2011, 164:1753-1766.
70. van Roermund C.W., Visser W.F., Ijlst L., Waterham H.R., Wanders R.J. Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid beta-oxidation. Biochim. Biophys. Acta 2011, 1811:148-152.
71. Van O.H., Denizot Y., Baes M., Van Veldhoven P.P. On the presence of C2-ceramide in mammalian tissues: possible relationship to etherphospholipids and phosphorylation by ceramide kinase. Biol. Chem. 2007, 388:315-324.
72. Ferdinandusse S., Ylianttila M.S., Gloerich J., Koski M.K., Oostheim W., Waterham H.R., Hiltunen J.K., Wanders R.J., Glumoff T. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. Am. J. Hum. Genet. 2006, 78:112-124.
73. Huyghe S., Mannaerts G.P., Baes M., Van Veldhoven P.P. Peroxisomal multifunctional protein-2: the enzyme, the patients and the knockout mouse model. Biochim. Biophys. Acta 2006, 1761:973-994.
74. Hayashi H., Oohashi M. Incorporation of acetyl-CoA generated from peroxisomal beta-oxidation into ethanolamine plasmalogen of rat liver. Biochim. Biophys. Acta 1995, 1254:319-325.
75. Krysko O., Bottelbergs A., Van V.P., Baes M. Combined deficiency of peroxisomal beta-oxidation and ether lipid synthesis in mice causes only minor cortical neuronal migration defects but severe hypotonia. Mol. Genet. Metab. 2010, 100:71-76.
76. Kou J., Kovacs G.G., Hoftberger R., Kulik W., Brodde A., Forss-Petter S., Honigschnabl S., Gleiss A., Brugger B., Wanders R., Just W., Budka H., Jungwirth S., Fischer P., Berger J. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol. 2011, 122:271-283.
77. Grimm M.O., Kuchenbecker J., Rothhaar T.L., Grosgen S., Hundsdorfer B., Burg V.K., Friess P., Muller U., Grimm H.S., Riemenschneider M., Hartmann T. Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J. Neurochem. 2011, 116:916-925.
78. Hartmann T., Kuchenbecker J., Grimm M.O. Alzheimer's disease: the lipid connection. J. Neurochem. 2007, 103(Suppl. 1):159-170.
79. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:65-77.
80. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 2001, 26:771-782.
81. Dragonas C., Bertsch T., Sieber C.C., Brosche T. Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson's disease. Clin. Chem. Lab. Med. 2009, 47:894-897.
82. Moraitou M., Dimitriou E., Zafeiriou D., Reppa C., Marinakis T., Sarafidou J., Michelakakis H. Plasmalogen levels in Gaucher disease. Blood Cells Mol. Dis. 2008, 41:196-199.
83. Wood P.L., Smith T., Pelzer L., Goodenowe D.B. Targeted metabolomic analyses of cellular models of Pelizaeus-Merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction. Lipids Health Dis. 2011, 10:102.
84. Ginsberg L., Rafique S., Xuereb J.H., Rapoport S.I., Gershfeld N.L. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 1995, 698:223-226.
85. Goodenowe D.B., Cook L.L., Liu J., Lu Y., Jayasinghe D.A., Ahiahonu P.W., Heath D., Yamazaki Y., Flax J., Krenitsky K.F., Sparks D.L., Lerner A., Friedland R.P., Kudo T., Kamino K., Morihara T., Takeda M., Wood P.L. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 2007, 48:2485-2498.
86. Singh I., Pujol A. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol. 2010, 20:838-844.
87. Brites P., Motley A.M., Gressens P., Mooyer P.A., Ploegaert I., Everts V., Evrard P., Carmeliet P., Dewerchin M., Schoonjans L., Duran M., Waterham H.R., Wanders R.J., Baes M. Impaired neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata. Hum. Mol. Genet. 2003, 12:2255-2267.
88. Baldwin E.J., Gibberd F.B., Harley C., Sidey M.C., Feher M.D., Wierzbicki A.S. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:954-957.
89. Brites P., Mooyer P.A., El M.L., Waterham H.R., Wanders R.J. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 2009, 132:482-492.
90. Braverman N., Zhang R., Chen L., Nimmo G., Scheper S., Tran T., Chaudhury R., Moser A., Steinberg S. A Pex7 hypomorphic mouse model for plasmalogen deficiency affecting the lens and skeleton. Mol. Genet. Metab. 2010, 99:408-416.
91. Bams-Mengerink A.M., Majoie C.B., Duran M., Wanders R.J., Van H.J., Scheurer C.D., Barth P.G., Poll-The B.T. MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 2006, 66:798-803.
92. Nuoffer J.M., Pfammatter J.P., Spahr A., Toplak H., Wanders R.J., Schutgens R.B., Wiesmann U.N. Chondrodysplasia punctata with a mild clinical course. J. Inherit. Metab. Dis. 1994, 17:60-66.
93. Rodemer C., Thai T.P., Brugger B., Kaercher T., Werner H., Nave K.A., Wieland F., Gorgas K., Just W.W. Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 2003, 12:1881-1895.
94. Pike L.J., Han X., Chung K.N., Gross R.W. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 2002, 41:2075-2088.
95. Komljenovic D., Sandhoff R., Teigler A., Heid H., Just W.W., Gorgas K. Disruption of blood-testis barrier dynamics in ether-lipid-deficient mice. Cell Tissue Res. 2009, 337:281-299.
96. Teigler A., Komljenovic D., Draguhn A., Gorgas K., Just W.W. Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum. Hum. Mol. Genet. 2009, 18:1897-1908.
97. Liegel R., Chang B., Dubielzig R., Sidjanin D.J. Blind sterile 2 (bs2), a hypomorphic mutation in Agps, results in cataracts and male sterility in mice. Mol. Genet. Metab. 2011, 103:51-59.
98. Acar N., Gregoire S., Andre A., Juaneda P., Joffre C., Bron A.M., Creuzot-Garcher C.P., Bretillon L. Plasmalogens in the retina: in situ hybridization of dihydroxyacetone phosphate acyltransferase (DHAP-AT)-the first enzyme involved in their biosynthesis-and comparative study of retinal and retinal pigment epithelial lipid composition. Exp. Eye Res. 2007, 84:143-151.
99. Thai T.P., Rodemer C., Worsch J., Hunziker A., Gorgas K., Just W.W. Synthesis of plasmalogens in eye lens epithelial cells. FEBS Lett. 1999, 456:263-268.
100. Martinez M., Ballabriga A., Gil-Gibernau J.J. Lipids of the developing human retina: I. Total fatty acids, plasmalogens, and fatty acid composition of ethanolamine and choline phosphoglycerides. J. Neurosci. Res. 1988, 20:484-490.
101. Broekhuyse R.M. Phospholipids in tissues of the eye. 3. Composition and metabolism of phospholipids in human lens in relation to age and cataract formation. Biochim. Biophys. Acta 1969, 187:354-365.
102. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res. 1992, 583:171-182.
103. Basbug M., Serin I.S., Ozcelik B., Gunes T., Akcakus M., Tayyar M. Prenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata by detection of rhizomelic shortening and bilateral cataracts. Fetal Diagn. Ther. 2005, 20:171-174.
104. Eustis H.S., Yaplee S.M., Kogutt M., Ginsberg H.G. Microspherophakia in association with the rhizomelic form of chondrodysplasia punctata. J. Pediatr. Ophthalmol. Strabismus 1990, 27:237-241.
105. Gilbert E.F., Opitz J.M., Spranger J.W., Langer L.O., Wolfson J.J., Viseskul C. Chondrodysplasia punctata-rhizomelic form. Pathologic and radiologic studies of three infants. Eur. J. Pediatr. 1976, 123:89-109.
106. Nenicu A., Luers G.H., Kovacs W., David M., Zimmer A., Bergmann M., Baumgart-Vogt E. Peroxisomes in human and mouse testis: differential expression of peroxisomal proteins in germ cells and distinct somatic cell types of the testis. Biol. Reprod. 2007, 77:1060-1072.
107. Luers G.H., Thiele S., Schad A., Volkl A., Yokota S., Seitz J. Peroxisomes are present in murine spermatogonia and disappear during the course of spermatogenesis. Histochem. Cell Biol. 2006, 125:693-703.
108. Reisse S., Rothardt G., Volkl A., Beier K. Peroxisomes and ether lipid biosynthesis in rat testis and epididymis. Biol. Reprod. 2001, 64:1689-1694.
109. Gorgas K., Teigler A., Komljenovic D., Just W.W. The ether lipid-deficient mouse: tracking down plasmalogen functions. Biochim. Biophys. Acta 2006, 1763:1511-1526.
110. Faust P.L., Banka D., Siriratsivawong R., Ng V.G., Wikander T.M. Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain. J. Inherit. Metab. Dis. 2005, 28:369-383.
111. Kirschner D.A., Inouye H., Ganser A.L., Mann V. Myelin membrane structure and composition correlated: a phylogenetic study. J. Neurochem. 1989, 53:1599-1609.
112. Wiese S., Gronemeyer T., Brites P., Ofman R., Bunse C., Renz C., Meyer H.E., Wanders R.J.A., Warscheid B. Comparative profiling of the peroxisomal proteome of wildtype and Pex7 knockout mice by quantitative mass spectrometry. Int. J. Mass Spectrom. 2012, 312:30-40.
113. Wood P.L., Khan M.A., Smith T., Ehrmantraut G., Jin W., Cui W., Braverman N.E., Goodenowe D.B. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis. 2011, 10:182.
114. Brites P., Ferreira A.S., Ferreira da S.T., Sousa V.F., Malheiro A.R., Duran M., Waterham H.R., Baes M., Wanders R.J. Alkyl-glycerol rescues plasmalogen levels and pathology of ether-phospholipid deficient mice. PLoS One 2011, 6:e28539.